DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Osimertinib
Drug: Selumetinib

First Posted Date: 2018-01-05

Last Posted Date: 2025-01-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT03392246

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

SHARE (Sharing Goals and Preferences) Study

Not Applicable

Completed

Conditions: Other Cancer

Interventions: Other: More Good Days video&brief questionnaire

First Posted Date: 2018-01-05

Last Posted Date: 2022-03-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 53

Registration Number: NCT03392090

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Nancy Keating, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute at St Elizabeth, Boston, Massachusetts, United States

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

Not Applicable

Active, not recruiting

Conditions: Brain Metastases
Small Cell Lung Cancer

Interventions: Radiation: Stereotactic Radiation

First Posted Date: 2018-01-05

Last Posted Date: 2024-10-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT03391362

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal

Not Applicable

Completed

Conditions: Gastrointestinal Cancer
Gynecologic Cancer

Interventions: Other: Enhanced Discharge Planning (EDP)
Behavioral: BOLSTER

First Posted Date: 2017-12-08

Last Posted Date: 2023-10-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 121

Registration Number: NCT03367247

Locations: 🇺🇸
25873, Boston, Massachusetts, United States

Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer

Not Applicable

Completed

Conditions: Ovarian Cancer

Interventions: Other: Fitness Tracker
Other: Social Incentive (Way to Health)

First Posted Date: 2017-12-06

Last Posted Date: 2023-10-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT03364673

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Phase 1

Active, not recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab
Biological: Neo Vax
Drug: Pembrolizumab

First Posted Date: 2017-12-05

Last Posted Date: 2025-04-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT03361852

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Phase 2

Active, not recruiting

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Nivolumab
Drug: Lirilumab

First Posted Date: 2017-11-14

Last Posted Date: 2024-06-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT03341936

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

HealthSmart: Promoting Healthy Lifestyles for Young Adult Cancer Survivors Using Educational Videos

Not Applicable

Completed

Conditions: Environmental Exposure to Ultraviolet Light

Interventions: Other: THE INFORMATION + APPEARANCE VIDEO
Other: Sleep hygiene video
Other: Information SunSmart video

First Posted Date: 2017-11-13

Last Posted Date: 2022-05-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 266

Registration Number: NCT03340532

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Nivolumab Combined with Ipilimumab for Patients with Advanced Rare Genitourinary Tumors

Phase 2

Active, not recruiting

Conditions: Genitourinary Cancer
Adrenocortical Carcinoma
Non-urothelial Bladder
Non-urothelial Upper Tract
Penile Cancer
Non-adenocarcinoma Prostate Cancer
Refractory Germ-cell
High Grade Neuroendocrine Carcinoma/small Cell Carcinoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2017-11-07

Last Posted Date: 2025-03-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT03333616

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
University of California, San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Physical Activity In Gastrointestinal Cancer

Not Applicable

Completed

Conditions: Metastatic Gastrointestinal Cancer
Physical Activity

Interventions: Other: Physical Activity Program

First Posted Date: 2017-11-06

Last Posted Date: 2020-03-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT03331406

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Home Terms & Conditions Privacy Policy